Femasys Inc logo

Femasys Inc(FEMY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.42
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FEMY

11/13/2026: FEMY (1-star) is currently NOT-A-BUY. Pass it for now.

Femasys Inc. is a micro-cap biomedical company focused on developing and commercializing innovative diagnostic and therapeutic products for women's reproductive health. The company's primary business strengths lie in its proprietary product portfolio, including commercialized tools like FemVue and newer offerings such as FemaSeed. Its core investment story centers on growth potential tied to expanding fertility solutions and advancing its non-surgical permanent birth control candidate, FemBloc. Key risks include ongoing operating losses, early-stage revenue scaling, equity dilution from funding needs, and stringent regulatory hurdles. Femasys suits speculative growth investors willing to monitor clinical milestones, regulatory updates, and commercial execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveFemasys offers high-growth optionality tied to its novel reproductive health pipeline and potential regulatory catalysts.
Momentum investorWeak fitMomentum fit is conditional on a positive upturn signal given recent share price consolidation.
Value investorWeak fitThe company lacks current profitability and positive earnings, making it unsuitable for traditional value strategies.
Dividend investorWeak fitFemasys does not pay dividends and retains all capital for clinical and commercial operations.
Low-risk investorWeak fitHigh clinical development risks and share price volatility create significant risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences wide price swings driven by clinical trial updates and financing news.
Valuation riskHighValuation depends heavily on forward-looking expectations for unapproved pipeline assets.
Competition risk (biomedical and reproductive health technology)Medium / highThe company competes against entrenched medical procedures and well-funded healthcare entities.
Business qualityMediumWhile innovative, the business is early-stage with modest revenue streams.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies entirely on clinical trial outcomes, regulatory clearances, and commercial adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.89M USD
Price to earnings Ratio -
1Y Target Price 16.5
Price to earnings Ratio -
1Y Target Price 16.5
Volume (30-day avg) 101.8K shares
Beta -2.17
52 Weeks Range 1.25 - 20.80
Updated Date 11/15/2026
52 Weeks Range 1.25 - 20.80
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.28

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 29.78%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FEMY receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
FEMY has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+1.0%) and strong revenue growth (+40.8%) are partially offset by weak cash generation (FCF margin -837.9%), weak profitability (net margin -812.3%), modest insider ownership of 4.02%.

Financial Health Rating

★★★★★
FEMY's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 61.9%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is FEMY's strongest growth driver at +40.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (+1.0%, moderate) and free-cash-flow growth (+4.9%, moderate) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 55.0% and approximately 82.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.02% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Dauntless Investment Group, LLC 22.30%
Vanguard Capital Management, LLC 0.74%
Jane Street Group LLC 0.63%
Geode Capital Management, LLC 0.37%
UBS Group AG 0.22%

Unit Economics (Per $1K Revenue)

★★★★★
FEMY generates approximately $620 of gross profit, $-7,670 of operating income, and $-8,379 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.01% (Tax Credit)

Quantitative Style Profile

★★★★★
FEMY has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Diagnostic Medical DevicesSales of commercialized products like FemVue and FemCerv to OB/GYN physicians and clinics.Provides baseline commercial revenue from established office diagnostic tools.
Fertility and Therapeutic SolutionsCommercialization of products like FemaSeed for specialized infertility treatments.Represents the primary near-term driver for expanding top-line revenue growth.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 15.24M
Price to Sales(TTM) 5.17
Enterprise Value 15.24M
Price to Sales(TTM) 5.17
Enterprise Value to Revenue 6.63
Enterprise Value to EBITDA 0.24
Shares Outstanding 8.38M
Shares Floating 6.88M
Shares Outstanding 8.38M
Shares Floating 6.88M
Percent Insiders 4.02
Percent Institutions 55.01

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.